menu
    • menu
    [{"orgOrder":0,"company":"Arcus Biosciences","sponsor":"Taiho Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Licensing Agreement","leadProduct":"AB154","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"Arcus Biosciences","amount2":0.28000000000000003,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.28000000000000003,"dosageForm":"","sponsorNew":"Arcus Biosciences \/ Taiho Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Arcus Biosciences \/ Taiho Pharmaceutical"},{"orgOrder":0,"company":"Arcus Biosciences","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"AB154","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"Arcus Biosciences","amount2":2,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":2,"dosageForm":"","sponsorNew":"Arcus Biosciences \/ Gilead Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Arcus Biosciences \/ Gilead Sciences"},{"orgOrder":0,"company":"Infinity Pharmaceuticals","sponsor":"Arcus Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Eganelisib","moa":"PI3K gamma","graph1":"Oncology","graph2":"Phase II","graph3":"Infinity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Infinity Pharmaceuticals \/ Arcus Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Infinity Pharmaceuticals \/ Arcus Biosciences"},{"orgOrder":0,"company":"Arcus Biosciences","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Domvanalimab","moa":"TIGIT","graph1":"Oncology","graph2":"Phase III","graph3":"Arcus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arcus Biosciences \/ Gilead","highestDevelopmentStatusID":"10","companyTruncated":"Arcus Biosciences \/ Gilead"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Arcus Bioscience","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Etrumadenant","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gilead Sciences \/ Arcus Bioscience","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Arcus Bioscience"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Arcus Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Etrumadenant","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gilead Sciences \/ Arcus Biosciences","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Arcus Biosciences"},{"orgOrder":0,"company":"Arcus Biosciences","sponsor":"Taiho Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Quemliclustat","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Arcus Biosciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Arcus Biosciences \/ Taiho Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Arcus Biosciences \/ Taiho Pharmaceutical"}]

    Find Clinical Drug Pipeline Developments & Deals for Etrumadenant

    Menu

    Etrumadenant

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Arcus Biosciences

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Arcus Biosciences

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Quemliclustat,Zimberelimab,Etrumadenant

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Taiho Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Taiho Exercises License Option for Quemliclustat in Japan and Asia

                            Details : Under the license agreement, Taiho will further support the development & commercialization of AB680 (quemliclustat) & will operationalize the PRISM-1 study in Japan as part of its mission.

                            Brand Name : AB680

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 08, 2024

                            Lead Product(s) : Quemliclustat,Zimberelimab,Etrumadenant

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Taiho Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Gilead Sciences

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Gilead Sciences

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Etrumadenant,Zimberelimab

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Arcus Biosciences

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Anti-TIGIT Domvanalimab-Containing Study Arms Improve Progression-Free Survival Compared to Anti-PD1 Alone in ...

                            Details : Domvanalimab is an Fc-silent investigational monoclonal antibody that is designed to bind to TIGIT, a protein receptor on immune cells that acts as a brake on the immune response.

                            Brand Name : AB154

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            December 19, 2022

                            Lead Product(s) : Etrumadenant,Zimberelimab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Arcus Biosciences

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Gilead Sciences

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Gilead Sciences

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Etrumadenant,Zimberelimab

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Arcus Bioscience

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Gilead and Arcus Biosciences Announce Positive Update on Joint TIGIT Program From Interim Analysis of ARC-7 St...

                            Details : Domvanalimab is an Fc-silent investigational monoclonal antibody that is designed to bind to TIGIT, a protein receptor on immune cells that acts as a brake on the immune response.

                            Brand Name : AB154

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            November 28, 2022

                            Lead Product(s) : Etrumadenant,Zimberelimab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Arcus Bioscience

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Arcus Biosciences

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Arcus Biosciences

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Domvanalimab,Zimberelimab,Etrumadenant

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Gilead Sciences

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Anti-TIGIT Domvanalimab-Based Combinations Showed Clinical Activity in People with Metastatic, PDL1-High Non-S...

                            Details : ARC-7 and the ongoing ARC-10 Phase 3 registrational study will continue to enroll as planned, and preparations for additional Phase 3 studies are underway for domvanalimab-based combinations across various cancer types.

                            Brand Name : AB154

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            June 24, 2021

                            Lead Product(s) : Domvanalimab,Zimberelimab,Etrumadenant

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Gilead Sciences

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Infinity Pharmaceuticals

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Infinity Pharmaceuticals

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Eganelisib,Etrumadenant

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Arcus Biosciences

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Infinity to Present at New York Academy of Sciences’ Frontiers in Cancer Immunotherapy 2021

                            Details : The Phase 1b clinical trial is a global multi-center, open-label trial of CERC-007 that will enroll around 12 subjects with active adult onset Still’s disease with a primal goal of the study will be to determine the safety and tolerability of CERC-007 ...

                            Brand Name : IPI-549

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 05, 2021

                            Lead Product(s) : Eganelisib,Etrumadenant

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Arcus Biosciences

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Arcus Biosciences

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Arcus Biosciences

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Zimberelimab,Etrumadenant,AB154

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Gilead Sciences

                            Deal Size : $2,000.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Gilead Sciences and Arcus Biosciences Ink Partnership to Co-develop and Co-commercialize Next-generation Cance...

                            Details : Under this agreement, Gilead Gains Broad Access to Arcus’s Clinical and Preclinical Pipeline of Immuno-Oncology Product Candidates that Target Critical Biological Pathways. Arcus to continue to independently conduct research on New Targets.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : $175.0 million

                            May 27, 2020

                            Lead Product(s) : Zimberelimab,Etrumadenant,AB154

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Gilead Sciences

                            Deal Size : $2,000.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Arcus Biosciences

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Arcus Biosciences

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Zimberelimab,Etrumadenant,AB154

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Taiho Pharmaceutical

                            Deal Size : $275.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Arcus Biosciences and Taiho Pharmaceutical Announce Taiho’s Exercise of an Exclusive License to Zimberelimab

                            Details : Taiho’s in-licensing facilitates global development and commercialization of zimberelimab as a monotherapy and as a combination backbone for Arcus’s and Taiho’s oncology portfolios.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            February 26, 2020

                            Lead Product(s) : Zimberelimab,Etrumadenant,AB154

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Taiho Pharmaceutical

                            Deal Size : $275.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth